Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00984-26 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Yuming Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious …. Hauptthemen laut MEDLINE: Adenosine, Anti-HIV Agents, HIV Infections. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
HIV infection remains a critical global public health concern. A potential long-acting therapeutic agent, 4′-ethynyl-2-fluoroadenosine analog 1c (CL-197), was investigated in a first-in-human phase 1 clinical trial. This single-center, randomized, double-blind, dose-escalation, placebo-controlled study assessed the safety and pharmacokinetics (PKs) of five doses of CL-197 (1, 10, 30, 60, and 100 mg) in healthy adults aged 18–45 years. The 1 mg group was open-label ( n = 4), while the other groups were randomized 4:1 to CL-197 or placebo. The primary endpoints were safety and tolerability. The PK evaluation involved the characterization of systemic exposure parameters (based on plasma drug concentrations and peripheral blood mononuclear cell [PBMC] drug concentrations) and urinary excretion parameters. CL-197 was well tolerated at all dose levels. The most frequently reported adverse reactions were sinus arrhythmia, followed by decreased apolipoprotein B, decreased blood iron, increased triglycerides, and elevated low-density lipoprotein. Plasma PKs showed dose-proportional exposure, with a mean time to maximum plasma concentration ( T max ) of 0.50–1.00 h. As the dose increased, the elimination time was prolonged. The plasma drug concentrations were approximately dose-proportional, whereas AUC 0-t and AUC 0-∞ exhibited non-linear characteristics within the range of 1-100mg, with the mean elimination half-life ( t 1/2 ) increasing from 1.39 to 10.20 h across doses. The mean t 1/2 in PBMCs was 61.29 h and 43.80 h in the 30 mg and 60 mg dose groups, respectively, and the median T max was 12 h. In conclusion, a single administration of CL-197 demonstrated an acceptable safety profile in younger adults. The intracellular CL-197-TP in PBMCs had a long half-life, providing preliminary support for the potential use of extended dosing intervals in further development. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT05944848 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
- China-Japan Friendship Hospital, Beijing, China.
- Henan Genuine Biotech Co., Ltd., Pingdingshan, Henan, China.
ORCID-Profile: Yuming Guo, Yonggang Li, Yi Ou, Na Guo, Fu-Sheng Wang
Förderung
- Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
Zitieren
APA
Guo, Y., Li, Y., Zhao, P., Bi, J., Gou, C., Chuai, Z., Yu, S., Zhang, R., Du, J., Ou, Y., Xu, R., Guo, N., Wang, F. S., & Li, Y. (2026). Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00984-26
Vancouver
Guo Y, Li Y, Zhao P, Bi J, Gou C, Chuai Z, et al. Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00984-26
BibTeX
@article{Guo2026,
author = {Guo, Yuming and Li, Yonggang and Zhao, Pan and Bi, Jingfeng and Gou, Chaoyun and Chuai, Zhengran and Yu, Shuangjie and Zhang, Renjie and Du, Jinfa and Ou, Yi and Xu, Ruonan and Guo, Na and Wang, Fu-Sheng and Li, Yuanyuan},
title = {Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00984-26}
}
EUVIMED